Leerink Partnrs Estimates Allakos FY2029 Earnings

Allakos Inc. (NASDAQ:ALLK) – Equities researchers at Leerink Partnrs issued their FY2029 earnings estimates for shares of Allakos in a research report issued on Wednesday, February 5th. Leerink Partnrs analyst T. Smith forecasts that the company will post earnings of ($0.20) per share for the year. The consensus estimate for Allakos’ current full-year earnings is ($1.16) per share.

Allakos (NASDAQ:ALLK) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.01.

ALLK has been the subject of a number of other research reports. Citizens Jmp cut Allakos from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 27th. Piper Sandler downgraded shares of Allakos from a “strong-buy” rating to a “hold” rating in a report on Monday, January 27th. Four investment analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $2.00.

Allakos Stock Performance

Shares of NASDAQ ALLK opened at $0.28 on Thursday. The business’s 50-day simple moving average is $0.94 and its 200-day simple moving average is $0.87. Allakos has a 52 week low of $0.23 and a 52 week high of $1.69. The firm has a market cap of $24.92 million, a price-to-earnings ratio of -0.14 and a beta of 0.78.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in ALLK. FMR LLC boosted its position in shares of Allakos by 14.6% in the third quarter. FMR LLC now owns 5,370,247 shares of the company’s stock valued at $3,508,000 after acquiring an additional 685,623 shares during the period. Geode Capital Management LLC raised its stake in Allakos by 8.9% during the 3rd quarter. Geode Capital Management LLC now owns 988,171 shares of the company’s stock valued at $646,000 after purchasing an additional 80,763 shares during the last quarter. Point72 Asset Management L.P. bought a new stake in Allakos in the 3rd quarter valued at $1,143,000. GSA Capital Partners LLP increased its holdings in shares of Allakos by 11.9% during the 3rd quarter. GSA Capital Partners LLP now owns 794,896 shares of the company’s stock worth $519,000 after purchasing an additional 84,750 shares during the period. Finally, Cubist Systematic Strategies LLC acquired a new position in shares of Allakos during the second quarter valued at about $55,000. 84.64% of the stock is owned by institutional investors.

Allakos Company Profile

Allakos Inc, a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company’s lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications.